Blepharitis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Blepharitis – Pipeline Review, H1 2018’, provides an overview of the Blepharitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Blepharitis

– The report reviews pipeline therapeutics for Blepharitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Blepharitis therapeutics and enlists all their major and minor projects

– The report assesses Blepharitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Blepharitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Blepharitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Hovione FarmaCiencia SA

InSite Vision Inc

Kala Pharmaceuticals Inc

Marinomed Biotechnologie GmbH

Merck & Co Inc

NicOx SA

Novaliq GmbH

Quorum Innovations LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Blepharitis Overview

Blepharitis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Blepharitis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Blepharitis Companies Involved in Therapeutics Development

Allergan Plc

Hovione FarmaCiencia SA

InSite Vision Inc

Kala Pharmaceuticals Inc

Marinomed Biotechnologie GmbH

Merck & Co Inc

NicOx SA

Novaliq GmbH

Quorum Innovations LLC

Blepharitis Drug Profiles

(doxycycline + omega 3 fatty acid) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGN-195263 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

azithromycin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISV-305 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISV-405 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

loteprednol etabonate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-03 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qi-402 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Blepharitis and Conjunctivitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetracycline Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Blepharitis Dormant Projects

Blepharitis Product Development Milestones

Featured News & Press Releases

Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis

Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSiteâ„¢ for the Treatment of Blepharitis in Adults

Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Blepharitis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Blepharitis Pipeline by Allergan Plc, H1 2018

Blepharitis Pipeline by Hovione FarmaCiencia SA, H1 2018

Blepharitis Pipeline by InSite Vision Inc, H1 2018

Blepharitis Pipeline by Kala Pharmaceuticals Inc, H1 2018

Blepharitis Pipeline by Marinomed Biotechnologie GmbH, H1 2018

Blepharitis Pipeline by Merck & Co Inc, H1 2018

Blepharitis Pipeline by NicOx SA, H1 2018

Blepharitis Pipeline by Novaliq GmbH, H1 2018

Blepharitis Pipeline by Quorum Innovations LLC, H1 2018

Blepharitis Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Blepharitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports